Pheochromocytoma and paraganglioma: Molecular testing and personalized medicine

Current Opinion in Oncology

Volumn 28, Issue 1, 2016, Pages 5-10

  Burnichon, Nelly ^a,b,c   Buffet, Alexandre ^a,b   Gimenez Roqueplo, Anne Paule ^a,b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Genetic testing; next generation sequencing; paragangliomas; personalized medicine

Indexed keywords

AXITINIB; DECITABINE; FUMARATE HYDRATASE; MALATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAX PROTEIN; PPGL PROTEIN; PROTEIN; PROTEIN TMEM127; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CLUSTER 1 RELATED GENE; CLUSTER 2 RELATED GENE; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; PARAGANGLIOMA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; ADRENAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; PROCEDURES;

ADRENAL GLAND NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRECISION MEDICINE;

EID: 84951566996     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000249     Document Type: Review

References (50)

1. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-851.
2. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014; 14:108-119.
3. Crona J, Nordling M, Maharjan R, et al. Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours. PLoS One 2014; 9:e86756.
4. Castro-Vega LJ, Letouze E, Burnichon N, et al. Multiomics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun 2015; 6:6044.
5. Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 2013; 15:356-371.
6. Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 2014; 171:R111-122.
7. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69:49-54.
8. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19:3011-3020.
9. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325:1139-1142.
10. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268-270.
11. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010; 42:229-233.
12. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663-667.
13. Cascon A, Comino-Mendez I, Curras-Freixes M, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst 2015; 107; 053.
14. Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005; 1:72-80.
15. Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010; 24:2382-2391.
16. Burnichon N, Vescovo L, Amar L, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011; 20:3974-3985.
17. Letouze E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23:739-752.
18. de Cubas AA, Leandro-Garcia LJ, Schiavi F, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer 2013; 20:477-493.
19. de Cubas AA, Korpershoek E, Inglada-Perez L, et al. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers. Clin Cancer Res 2015; 21:3020-3030.
20. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007; 92:3822-3828.
21. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63:5615-5621.
22. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 2009; 266:19-42.
23. Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367:922-930.
24. Castro-Vega LJ, Buffet A, De Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 2014; 23:2440-2446.
25. Clark GR, Sciacovelli M, Gaude E, et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab 2014; 99:E2046-E2050.
26. Comino-Mendez I, de Cubas AA, Bernal C, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 2013; 22:2169-2176.
27. Welander J, Andreasson A, Brauckhoff M, et al. Frequent EPAS1/HIF2alpha exons 9 and 12 mutations in nonfamilial pheochromocytoma. Endocr Relat Cancer 2014; 21:495-504.
28. Buffet A, Smati S, Mansuy L, et al. Mosaicism in HIF2A-related polycythemiaparaganglioma syndrome. J Clin Endocrinol Metab 2014; 99:E369-E373.
29. Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014; 135:2711-2720.
30. Burnichon N, Buffet A, Parfait B, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012; 21:5397-5405.
31. Welander J, Larsson C, Backdahl M, et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 2012; 21:5406-5416.
32. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567-610.
33. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23:8812-8818.
34. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915-1942.
35. Burnichon N, Cascon A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012; 18:2828-2837.
36. Crona J, Delgado Verdugo A, Maharjan R, et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 2013; 98:E1266-1271.
37. Luchetti A, Walsh D, Rodger F, et al. Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. Int J Endocrinol 2015; 2015:138573.
38. Curras-Freixes M, Inglada-Perez L, Mancikova V, et al. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet 2015; 52:647-656.
39. Fishbein L, Khare S, Wubbenhorst B, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 2015; 6:6140.
40. Flynn A, Benn D, Clifton-Bligh R, et al. The genomic landscape of phaeochromocytoma. J Pathol 2015; 236:78-89.
41. Juhlin CC, Stenman A, Haglund F, et al. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. Genes Chromosomes Cancer 2015; 54:542-554.
42. Stenman A, Juhlin CC, Haglund F, et al. Absence of KMT2D/MLL2 mutations in abdominal paraganglioma. Clin Endocrinol (Oxf) 2015. [Epub ahead of print]
43. Papathomas TG, Oudijk L, Zwarthoff EC, et al. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocr Relat Cancer 2014; 21:653-661.
44. Liu T, Brown TC, Juhlin CC, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014; 21:427-434.
45. Casey R, Garrahy A, Tuthill A, et al. Universal genetic screening uncovers a novel presentation of an SDHAF2 mutation. J Clin Endocrinol Metab 2014; 99:E1392-1396.
46. Crona J, Verdugo AD, Granberg D, et al. Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocr Connect 2013; 2:104-111.
47. Rattenberry E, Vialard L, Yeung A, et al. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013; 98:E1248-E1256.
48. Welander J, Andreasson A, Juhlin CC, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2014; 99:E1352-E1360.
49. Toledo RA, Dahia PL. Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes. Curr Opin Endocrinol Diabetes Obes 2015; 22:169-179.
50. Crona J, Backman S, Maharjan R, et al. Spatio-temporal heterogeneity characterizes the genetic landscape of pheochromocytoma and defines early events in tumourigenesis. Clin Cancer Res 2015; 21:4451-4460.